Uric acid levels and metabolic shifts in hypertensive patients with moderate excretory dysfunction

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

BACKGROUND: Development of hyperuricemia — elevated level of uric acid — is often associated with arterial hypertension. Owing to the widespread prevalence of hyperuricemia in Russia, additional diagnostic markers and pathogenetic correlations between uric acid and other metabolic markers should be studied. In contrast to uric acid, homocysteine, citrulline, and homoarginine content in the blood depends on transmembrane transport and enzymatic reactions in kidney tissue.

AIM: To study the correlation between uric acid levels and metabolic dysfunction markers in hypertensive patients under moderate impairment of excretory function.

MATERIALS AND METHODS: The levels of uric acid, citrulline, homoarginine, total homocysteine, methionine, and other clinical and laboratory parameters were determined for 115 patients with arterial hypertension, with a median age and interquartile range of 64 [54–71] years and an estimated glomerular filtration rate of 45 ml/min/1.73 m2.

RESULTS: In 57 (50%) patients, the uric acid level exceeded the threshold value of 360 μM, indicating an increased risk of cardiovascular complications. Reduced metabolic functions of the kidneys under decreased citrulline, total homocysteine, methionine, and homoarginine levels in the entire group of patients and separately in subgroups of men and women were observed significantly more often than an elevated uric acid level or decreased estimated glomerular filtration rate. The uric acid level was positively correlated with markers of carbohydrate-lipid metabolism: triglycerides (Rs=0.334, p=0.018), glucose (Rs=0.252, p=0.046), and body mass index (Rs=0.396, p=0.001). Similar to uric acid, the homoarginine level showed a positive relationship with body mass index (Rs=0.302, p=0.003). After adjusting for gender and estimated glomerular filtration rate, an association analysis regarding the role of body mass index was performed. It was found that the close correlation between uric acid level and body mass index was significant over others (r=0.421, p=0.0011). In predicting uric acid levels, the relative contribution of estimated glomerular filtration rate and body mass index was equivalent according to multiple regression analysis, that is, an increase in uric acid levels is associated with both renal dysfunction and accumulation of adipose tissue.

CONCLUSION: Renal metabolic insufficiency with hyperuricemia under the initial stages of hypertension is asymptomatic, thus, additional markers have been proposed for the evaluation of remodeling of tissue metabolism in the kidneys, including citrulline, homoarginine, and total homocysteine.

Full Text

Restricted Access

About the authors

Aleksandr A. Zhloba

Academician I.P. Pavlov First St. Petersburg State Medical University

Author for correspondence.
Email: zhlobaaa@1spbgmu.ru
ORCID iD: 0000-0003-0605-7617
SPIN-code: 6096-2117
Scopus Author ID: 7004465896

MD, Dr. Sci. (Medicine), Professor

Russian Federation, 6-8 L. Tolstoy Str., bldg. 3, St. Petersburg, 197022

Tatiana F. Subbotina

Academician I.P. Pavlov First St. Petersburg State Medical University

Email: subbotina2002@mail.ru
ORCID iD: 0000-0002-2278-8391
SPIN-code: 9691-2123
Scopus Author ID: 6701446219

MD, Dr. Sci. (Medicine), Assistant Professor

Russian Federation, 6-8 L. Tolstoy Str., bldg. 3, St. Petersburg, 197022

References

  1. Chazova IE, Zhernakova YuV, et al. Clinical guidelines. Diagnosis and treatment of arterial hypertension. Systemic Hypertension. 2019,16(1):6–31. doi: 10.26442/2075082X.2019.1.190179
  2. Borghi C, Tykarski A, Widecka K, et al. Expert consensus for the diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk. Cardiol. J. 2018,25(5):545–563. doi: 10.5603/CJ.2018.0116
  3. Shalnova SA, Deev AD, Artamonov GV, et al. Hyperuricemia and its correlates in the Russian population (results of ESSE-RF epidemiological study). Rational Pharmacotherapy in Cardiology. 2014,10(2):153–159. doi: 10.20996/1819-6446-2014-10-2-153-159
  4. Chazova IE, Zhernakova JV, Kisliak OA, et al. Consensus on patients with hyperuricemia and high cardiovascular risk treatment. Systemic Hypertension. 2019,16(4):8–21. doi: 10.26442/2075082X.2019.4.190686.53
  5. Wen S, Arakawa H, Tamai I. Uric acid in health and disease: From physiological functions to pathogenic mechanisms. Pharmacol. Ther. 2024,256:108615. doi: 10.1016/j.pharmthera.2024.108615
  6. Bi M, Feng A, Liu Y, Tian S. U-shaped association of serum uric acid with cardiovascular disease risk scores and the modifying role of sex among Chinese adults. Nutr. Metab. Cardiovasc. Dis. 2023,33(5):1066–1076. doi: 10.1016/j.numecd.2023.02.025
  7. Roman YM. The role of uric acid in human health: insights from the uricase gene. J. Pers. Med. 2023,13(9):1409. doi: 10.3390/jpm13091409
  8. Sharaf El Din UAA, Salem MM, Abdulazim DO. Uric acid in the pathogenesis of metabolic, renal, and cardiovascular diseases: A review. J. Adv. Res. 2017,8(5):537–548. doi: 10.1016/j.jare.2016.11.004
  9. Girigoswami K, Arunkumar R, Girigoswami A. Management of hypertension addressing hyperuricaemia: introduction of nano-based approaches. Ann. Med. 2024,56(1):2352022. doi: 10.1080/07853890.2024.2352022
  10. Dwyer KM, Kishore BK, Robson SC. Conversion of extracellular ATP into adenosine: a master switch in renal health and disease. Nat. Rev. Nephrol. 2020,16(9):509–524. doi: 10.1038/s41581-020-0304-7
  11. Zhloba AA, Subbotina TF. The evaluation of folate status using total homocysteine in hypertensive patients. Medical Journal of the Russian Federation. 2019,25(3):158–165. doi: 10.18821/0869-2106-2019-25-3-158-165
  12. Zhloba AA, Subbotina TF, Reypolskaya TYu. The level of blood citrulline in hypertensive patients with abnormal renal excretory function. Russian Clinical Laboratory Diagnostics. 2023,68(3):133–140. doi: 10.51620/0869-2084-2023-68-3-133-140
  13. Zhloba AA, Subbotina TF. The evaluation of homoarginine and folic acid in patients with arterial hypertension. Russian Clinical Laboratory Diagnostics. 2020,65(8):474–481. doi: 10.18821/0869-2084-2020-65-8-474-481
  14. Patent RUS № 2609873/ 06.02.2017. Zhloba AA, Subbotina TF, Shipaeva KA. Method of determining homoarginine content in blood plasma and other human biological fluids. Available from: https://www.elibrary.ru/download/elibrary_38258690_29790170.pdf EDN: FTKBFA
  15. Zhloba AA, Subbotina TF. evaluation of homocysteine binding with a fraction of plasma proteins associated with vascular remodeling. Arterial Hypertension. 2013,19(2):184–188. doi: 10.18705/1607-419X-2013-19-2-184-188
  16. Tietz NW, editor. Clinical guide to laboratory tests. Moscow: Meditsina, 1986.
  17. Sakaguchi YM, Wiriyasermkul P, Matsubayashi M, et al. Identification of three distinct cell populations for urate excretion in human kidneys. J. Physiol. Sci. 2024 74(1):1. doi: 10.1186/s12576-023-00894-0
  18. Boban M, Kocic G, Radenkovic S, et al. Circulating purine compounds, uric acid, and xanthine oxidase/dehydrogenase relationship in essential hypertension and end stage renal disease. Ren. Fail. 2014,36(4):613–618. doi: 10.3109/0886022X.2014.882240
  19. D'Elia L, Masulli M, Cirillo P, et al. Serum uric acid/serum creatinine ratio and cardiovascular mortality in diabetic individuals-the uric acid right for heart health (URRAH) project. Metabolites. 2024,14(3):164. doi: 10.3390/metabo14030164
  20. Khasun MH, Rumyantsev ASh, Galkina OV, Korosteleva NYu. Urine uromodulin and angiotensin converting enzyme inhibitors: is there a relationship? Nephrology (Saint-Petersburg). 2022,26(1):69–74. doi: 10.36485/1561-6274-2022-26-1-69-74
  21. Iakovleva AV, Vertov NA, Zaleskiy MG, et al. A pathogenetic role of posttranslational isoforms of uromodulin. Biofizika. 2023,68(3):609–615. doi: 10.31857/S0006302923030225
  22. Gadaev AG, Dadabayeva RK. Assessment of the role of albuminuria and uromodulin in the early diagnosis of renal function disorders in some types of obesity phenotypes. Nephrology (Saint-Petersburg). 2024,28(1):72–79. doi: 10.36485/1561-6274-2024-28-1-72-79

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2024 Zhloba A.A., Subbotina T.F.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ:  ПИ № ФС 77 - 86785 от 05.02.2024 (ранее — ПИ № ФС 77 - 59057 от 22.08.2014).

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies